Building Biotech's Future: The Strategic Imperative Of AI Integration

What if the real unlock for biotech is not the next scientific breakthrough, but how bravely we are willing to redesign the way work gets done?​

For too long, small and mid-cap biotechs have been told the only way to compete is to copy Big Pharma’s org design at a smaller scale. The truth is that the model was never built for 20-person teams, 18-month runways, and the kind of existential trade-offs founders are making every quarter.

In my new article for Life Science Leader, I talk about why now is the moment to intentionally design AI into the operating system of a company, not as a side experiment but as core infrastructure.​

This is about more than productivity. It is about creating the kind of leverage that lets one exceptional regulatory leader, paired with an AI-native documentation system, move an IND forward in days instead of weeks without compromising quality or judgment. It is about freeing scientists, clinicians, and operators from manual, soul-sucking work so they can focus on what humans do best: pattern recognition, bold decision-making, and building the kind of organizations where transformative science actually has a shot at reaching patients.